Biolidics (SGX:8YY) loss for the third quarter of the year stood at SG$420,000, down nearly 30% year over year from SG$596,000, a filing with the Singapore Exchange said on Friday.
Loss per share came in at SG$0.0006 from SG$0.0007 in the year-ago period.
The diagnostic solutions provider's revenue was up 7% year over year to SG$15,000 from SG$14,000, mainly due to a slight increase in revenue from sales of CTChip FR1 biochip.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。